Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date July 29, 2022 · Filed August 25, 2022
Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2022 Filed May 25, 2022 18:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 286 | $48.76 | $13,946.56 |
DisclosureSEC source: 0001567619-22-011711 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,237 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 13, 2022 Filed May 17, 2022 17:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | PurchaseClass A Common Stock | 158 | $40.49 | $6,396.71 |
DisclosureSEC source: 0001567619-22-011119 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,523 F1 · kind: The purchase was made under the Issuer's 2019 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) under Rule 16b-3(c). Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 19:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 288 | $78.60 | $22,636.60 |
DisclosureSEC source: 0001567619-22-005519 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,365 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001567619-22-004884 · doc1.xml · derivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option, originally for 800,000 shares, of which 408,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 17,000 | $95.13 | $1,617,261.00 |
DisclosureSEC source: 0001567619-22-004884 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,653 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $95.00 to $95.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:48 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001567619-22-004884 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · derivative · entry 11 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 800,000 shares, of which 391,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3 | $125.00 | $375.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,653 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $124.44 | $12,444.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,656 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $123.53 | $12,353.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,756 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $122.94 | $12,294.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,856 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,200 | $121.77 | $389,648.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,956 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $121.47 to $122.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $120.93 | $133,024.54 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,156 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $120.31 to $121.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,017 | $119.28 | $121,311.22 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,256 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $118.985 to $119.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,185 | $118.32 | $613,498.53 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,273 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.90 to $118.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,195 | $117.53 | $728,071.09 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,458 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.89 to $117.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 16:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001567619-22-001197 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 49,910 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001567619-21-022503 · doc1.xml · derivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,757 Underlying: Class A Common Stock · 49,910 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, originally for 125,000 shares, of which 63,243 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vested each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 4,688 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001567619-21-022503 · doc1.xml · derivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,688 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, originally for 25,000 shares, of which 25,000 shares have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vested each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 49,910 | $5.04 | $251,546.40 |
DisclosureSEC source: 0001567619-21-022503 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 4,688 | $1.20 | $5,625.60 |
DisclosureSEC source: 0001567619-21-022503 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F7 · derivative.exercise_date: This option, originally for 800,000 shares, of which 374,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $142.47 | $14,247.00 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,055 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $141.31 | $113,048.80 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,155 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.02 to $141.895. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,701 | $140.38 | $238,791.82 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,955 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.01 to $140.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,599 | $139.52 | $1,339,239.04 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,656 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $139.00 to $139.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,235 | $138.60 | $448,373.91 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,255 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $138.00 to $138.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,565 | $137.63 | $215,395.80 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,490 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $137.00 to $137.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001567619-21-022118 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 281 | $148.38 | $41,695.09 |
DisclosureSEC source: 0001567619-21-021188 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,055 F1 · shares: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 357,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $168.34 | $16,834.00 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,336 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $167.27 | $16,727.00 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,436 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,776 | $165.89 | $792,305.92 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,536 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $165.51 to $166.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,872 | $164.87 | $1,132,962.59 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,312 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $164.50 to $165.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,122 | $164.18 | $676,733.47 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,184 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $163.50 to $164.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,030 | $163.10 | $167,994.34 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,306 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $162.49 to $163.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 18:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001567619-21-020599 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 18:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001567619-21-018312 · doc1.xml · derivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 340,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 18:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,043 | $158.63 | $482,715.65 |
DisclosureSEC source: 0001567619-21-018312 · doc1.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,336 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $158.09 to $159.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 18:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,997 | $157.40 | $1,258,759.79 |
DisclosureSEC source: 0001567619-21-018312 · doc1.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,379 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $156.95 to $157.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 18:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,960 | $156.49 | $932,678.02 |
DisclosureSEC source: 0001567619-21-018312 · doc1.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,376 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $155.95 to $156.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 18:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001567619-21-018312 · doc1.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · derivative · entry 14 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F12 · derivative.exercise_date: This option, originally for 800,000 shares, of which 323,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $184.32 | $18,432.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 13 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,336 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $181.24 | $18,123.50 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 12 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,436 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $178.90 | $89,451.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 11 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,536 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · price: This transaction was executed in multiple trades at prices ranging from $178.81 to $179.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $178.24 | $178,237.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,036 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $177.79 to $178.785. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $177.21 | $301,258.53 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,036 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $176.75 to $177.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,906 | $176.19 | $688,197.75 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,736 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $175.75 to $176.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.